Ellis Investment Partners’s Inovio Pharmaceuticals INO Stock Holding History

Ellis Investment Partners’s Portfolio INO Stock Details INO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-333	Closed	-$6K	–	446
2022 Q3	$6K	Hold	333	–	–	﹤0.01%	646
2022 Q2	$6K	Sell	333 -167	-33%	-$4.71K	﹤0.01%	657
2022 Q1	$21K	Sell	500 -8	-2%	-$360	0.01%	516
2021 Q4	$30K	Buy	508 +166	+49%	+$13.3K	0.01%	486
2021 Q3	$29K	Hold	342	–	–	0.01%	464
2021 Q2	$38K	Buy	342 +167	+95%	+$16K	0.01%	436
2021 Q1	$19K	Buy	175 +8	+5%	+$1.05K	0.01%	497
2020 Q4	$18K	Hold	167	–	–	0.01%	493
2020 Q3	$23K	Buy	167 +84	+101%	+$17.5K	0.01%	455
2020 Q2	$19K	Buy	+83	New	+$13.3K	0.01%	463

Other funds holding INO

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Rafferty Asset Management New York $24.6B AUM 47.06% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Ellis Investment Partners's INO Position: Q4 2022 in Review

Ellis Investment Partners sold out of Inovio Pharmaceuticals (INO) in Q4 2022, closing a stake of 333 shares — an estimated $6K sold.

Ellis Investment Partners first reported a position in INO in Q2 2020 and held it in 10 quarters. The position peaked at $38K in Q2 2021. 183 funds tracked by Wall St. Rank hold INO as of Q4 2022.

Ellis Investment Partners reported no remaining Inovio Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
Ellis Investment Partners sold 333 Inovio Pharmaceuticals shares in Q4 2022, an estimated $6K.
Ellis Investment Partners first reported a position in Inovio Pharmaceuticals in Q2 2020 and held it in 10 quarters.
Ellis Investment Partners's Inovio Pharmaceuticals position peaked at $38K in Q2 2021.
183 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q4 2022.

Based on Ellis Investment Partners's 13F filing for Q4 2022, filed 31 Jan 2023.